ערך בספרים למניה: cyclotherapeutics.com (CYTH)

Cyclo Therapeutics maintains pricing power due to the uniqueness of Trappsol Cyclo in treating Niemann-Pick disease. Its status as an expert in neurodegenerative pathologies strengthens brand trust. The net asset value per share demonstrates fundamental stability, with the value fixed at -0.47. Independence from macroeconomic factors makes the company a reliable defensive asset within its own product cycle.

Bioethical compliance and the environmental optimization of Cyclo Therapeutics laboratories directly impact the capital expenditure structure and the net asset value. The current value of -0.47 reflects the remaining equity per share in a hypothetical liquidation, which allows for an assessment of the business's fundamental margin of safety via the summary book value per share according to the Benjamin Graham methodology.